NewAmsterdam Pharma Company NV’s recent filing unveils that its Affiliate Douglas F Kling acquired Company’s shares for reported $11.6 million on Jan 27 ’25. In the deal valued at $23.20 per share,500,000 shares were bought.
Then, Mayur Somalya bought 200,000 shares, generating $4,640,000 in total proceeds.
Before that, NAP PoolCo B.V. bought 1,396,241 shares. NewAmsterdam Pharma Company NV shares valued at $35,338,860 were divested by the Affiliate at a price of $25.31 per share.
H.C. Wainwright initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published on December 30, 2024; the price target was $48. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Scotiabank began covering NAMS with “Sector outperform” recommendation on March 14, 2024. Guggenheim started covering the stock on January 18, 2024. It rated NAMS as “a Buy”.
Price Performance Review of NAMS
On Monday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock fall -3.48% to $20.27. Over the last five days, the stock has gained 15.63%. NewAmsterdam Pharma Company NV shares have fallen nearly -21.13% since the year began. Nevertheless, the stocks have fallen -14.18% over the past one year. While a 52-week high of $27.29 was reached on 01/02/25, a 52-week low of $15.19 was recorded on 02/25/25. SMA at 50 days reached $22.61, while 200 days put it at $19.77.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 19.82, which if violated will result in even more drops to 19.37. On the upside, there is a resistance level at 21.07. A further resistance level may holdings at 21.86. The Relative Strength Index (RSI) on the 14-day chart is 48.36, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.31, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 28.47%. Stochastics %K at 82.10% indicates the stock is a selling.
The most recent change occurred on January 16, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $37 price target.
